Current Diabetes Reports

, Volume 6, Issue 5, pp 357–364 | Cite as

Is the metabolic syndrome a real clinical entity and should it receive drug treatment?

Article

Abstract

Metabolic syndrome represents a cluster of risk factors commonly associated with obesity and diabetes that in turn are associated with an increased risk of cardiovascular disease. The worldwide prevalence of metabolic syndrome, obesity, and diabetes is on the rise, leading to serious public health concerns surrounding the downstream consequences in the form of premature cardiovascular disease. In this review, we examine the debate surrounding the characterization and diagnosis of metabolic syndrome and discuss potential treatment options.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.Google Scholar
  2. 2.
    World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Geneva: World Health Organization; 1999.Google Scholar
  3. 3.
    Ford ES, Giles WH: A comparison of the prevalence of the metabolic syndrome using two proposed Definitions. Diabetes Care 2003, 26:575–581.PubMedCrossRefGoogle Scholar
  4. 4.
    International Diabetes Federation: The IDF consensus worldwide Definition of the metabolic syndrome. http:// www.idf.org/webdata/docs/idf_Metasyndrome_Definition. pdf. Accessed May 2006.Google Scholar
  5. 5.
    Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.PubMedCrossRefGoogle Scholar
  6. 6.
    Sarti C, Gallagher J: The metabolic syndrome: prevalence, CHD risk, and treatment. J Diabetes Complications 2006, 20:121–132.PubMedCrossRefGoogle Scholar
  7. 7.
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210–1214.PubMedCrossRefGoogle Scholar
  8. 8.
    Stern MP, Williams K, Gonzalez-Villalpando C, et al.: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004, 27:2676–2681.PubMedCrossRefGoogle Scholar
  9. 9.
    McNeill AM, Rosamond WD, Girman CJ, et al.: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005, 28:385–390.PubMedCrossRefGoogle Scholar
  10. 10.
    Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304. Position statement from the American Diabetes Association and European Association for the Study of Diabetes on metabolic syndrome that examines the evidence for and against the use of metabolic syndrome in the clinic.PubMedCrossRefGoogle Scholar
  11. 11.
    Grant RW, Buse JB, Meigs JB: Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005, 28:337–442.PubMedCrossRefGoogle Scholar
  12. 12.
    Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.PubMedCrossRefGoogle Scholar
  13. 13.
    Reaven GM: The metabolic syndrome: requiescat in pace. Clin Chem 2005, 51:931–938.PubMedCrossRefGoogle Scholar
  14. 14.
    Carr DB, Utzschneider KM, Hull RL, et al.: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004, 53:2087–2094.PubMedCrossRefGoogle Scholar
  15. 15.
    Hutley L, Prins JB: Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 2005, 330:280–289. Reviews recent advances in adipocyte biology, focusing on the emerging role of the adipocyte in secreting biologically active "adipokines" and their function in both healthy and pathologic states.PubMedCrossRefGoogle Scholar
  16. 16.
    Unger RH: Hyperleptinemia: protecting the heart from lipid overload. Hypertension 2005, 45:1031–1034. Examines the physiologic role of leptin and proposes a unifying hypothesis regarding its function in lipid partitioning and the pathogenesis of obesity and CV disease.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhu S, St-Onge MP, Heshka S, Heymsfield SB: Lifestyle behaviours associated with lower risk of having the metabolic syndrome. Metabolism 2004, 53:1503–1511.PubMedCrossRefGoogle Scholar
  18. 18.
    Orchard TJ, Temprosa M, Goldberg R, et al.: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005, 142:611–619.PubMedGoogle Scholar
  19. 19.
    Ryan DH, Espeland MA, Foster GD, et al.: Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003, 24:610–628.PubMedCrossRefGoogle Scholar
  20. 20.
    Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.PubMedCrossRefGoogle Scholar
  21. 21.
    Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.PubMedCrossRefGoogle Scholar
  22. 22.
    Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410–418.PubMedCrossRefGoogle Scholar
  23. 23.
    Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597–2604.PubMedCrossRefGoogle Scholar
  24. 24.
    Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.PubMedCrossRefGoogle Scholar
  25. 25.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.: Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004, 18:781–788.PubMedCrossRefGoogle Scholar
  26. 26.
    Wolfe ML, Vartanian SF, Ross JL, et al.: Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001, 87:476–479.PubMedCrossRefGoogle Scholar
  27. 27.
    Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298.PubMedCrossRefGoogle Scholar
  28. 28.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998–3007.CrossRefGoogle Scholar
  29. 29.
    Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912.PubMedCrossRefGoogle Scholar
  30. 30.
    Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.PubMedCrossRefGoogle Scholar
  31. 31.
    Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895–906.PubMedCrossRefGoogle Scholar
  32. 32.
    Li Z, Maglione M, Tu W, et al.: Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532–546.PubMedGoogle Scholar
  33. 33.
    Reaven G, Segal K, Hauptman J, et al.: Effect of orlistatassisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001, 87:827–831.PubMedCrossRefGoogle Scholar
  34. 34.
    Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155–161.PubMedCrossRefGoogle Scholar
  35. 35.
    Lichtman AH, Cravatt BF: Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005, 115:1130–1133.PubMedCrossRefGoogle Scholar
  36. 36.
    Tonstad S: Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2006, 16:156–162.PubMedCrossRefGoogle Scholar
  37. 37.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761–775.PubMedCrossRefGoogle Scholar
  38. 38.
    Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389–1397.PubMedCrossRefGoogle Scholar
  39. 39.
    Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121–2134.PubMedCrossRefGoogle Scholar
  40. 40.
    Buchwald H, Avidor Y, Braunwald E, et al.: Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724–1737.PubMedCrossRefGoogle Scholar
  41. 41.
    Maggard MA, Shugarman LR, Suttorp M, et al.: Metaanalysis: surgical treatment of obesity. Ann Intern Med 2005, 142:547–559.PubMedGoogle Scholar
  42. 42.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.Google Scholar
  43. 43.
    Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643–2653.PubMedCrossRefGoogle Scholar
  44. 44.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–853.Google Scholar
  45. 45.
    Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993, 16:621–629.PubMedCrossRefGoogle Scholar
  46. 46.
    Charles MA, Eschwege E, Grandmottet P, et al.: Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000, 16:2–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854–865.Google Scholar
  48. 48.
    Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.PubMedCrossRefGoogle Scholar
  49. 49.
    Stumvoll M, Haring HU: Glitazones: clinical effects and molecular mechanisms. Ann Med 2002, 34:217–224.PubMedGoogle Scholar
  50. 50.
    Rosenblatt S, Miskin B, Glazer NB, et al.: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001, 12:413–423.PubMedCrossRefGoogle Scholar
  51. 51.
    Mayerson AB, Hundal RS, Dufour S, et al.: The effect of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002, 51:797–802.PubMedCrossRefGoogle Scholar
  52. 52.
    Rajagopalan R, Iyer S, Khan M: Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Curr Med Res Opin 2005, 21:163–172.PubMedCrossRefGoogle Scholar
  53. 53.
    Derosa G, Cicero AF, Gaddi A, et al.: Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelvemonth, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004, 26:744–754.PubMedCrossRefGoogle Scholar
  54. 54.
    Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.PubMedCrossRefGoogle Scholar
  55. 55.
    Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005, 48:1726–1735.PubMedCrossRefGoogle Scholar
  56. 56.
    Xiang AH, Peters RK, Kjos SL, et al.: Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006, 55:517–522.PubMedCrossRefGoogle Scholar
  57. 57.
    Gerstein HC, Yusuf S, Holman R, et al.: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004, 47:1519–1527.PubMedCrossRefGoogle Scholar
  58. 58.
    Nauck MA, Kleine N, Orskov C, et al.: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741–744.PubMedCrossRefGoogle Scholar
  59. 59.
    Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824–830.PubMedCrossRefGoogle Scholar
  60. 60.
    Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929–2940.PubMedCrossRefGoogle Scholar
  61. 61.
    BYETTA exenatide injection: Amylin Pharmaceuticals, Inc. http://pi.lilly.com/us/byetta-pi.pdf. Accessed May 2006.Google Scholar
  62. 62.
    Nielsen LL, Young AA, Parkes DG: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77–88.PubMedCrossRefGoogle Scholar
  63. 63.
    Blonde L, Klein EJ, Han J, et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436–447.PubMedCrossRefGoogle Scholar
  64. 64.
    Juhl CB, Hollingdal M, Sturis J, et al.: Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51:424–429.PubMedCrossRefGoogle Scholar
  65. 65.
    Madsbad S, Schmitz O, Ranstam J, et al.: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27:1335–1342.PubMedCrossRefGoogle Scholar
  66. 66.
    Balkan B, Kwasnik L, Miserendino R, et al.: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999, 42:1324–1331.PubMedCrossRefGoogle Scholar
  67. 67.
    Ahren B, Landin-Olsson M, Jansson PA, et al.: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:2078–2084.PubMedCrossRefGoogle Scholar
  68. 68.
    Ahren B, Simonsson E, Larsson H, et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25:869–875.PubMedCrossRefGoogle Scholar
  69. 69.
    Young AA: Amylin’s physiology and its role in diabetes. Curr Opin Endocrinol Diabetes 1997, 4:282–290.CrossRefGoogle Scholar
  70. 70.
    Kruger DF, Gloster MA: Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs 2004, 64:1419–1432.PubMedCrossRefGoogle Scholar
  71. 71.
    Ceriello A, Piconi L, Quagliaro L, et al.: Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005, 28:632–637.PubMedCrossRefGoogle Scholar
  72. 72.
    SYMLIN (pramlintide acetate) Injection. Amylin Pharmaceuticals, Inc. http://symlin.com/pdf/SYMLIN-picombined. pdf. Accessed May 2006.Google Scholar

Copyright information

© Current Science Inc. 2006

Authors and Affiliations

  1. 1.Amylin Pharmaceuticals, Inc.San DiegoUSA

Personalised recommendations